Clinical Scorecard: The Role of Melatonin in Protecting Mitochondria During Cardiac Ischemia-Reperfusion Injury: Insights, Mechanisms, and Clinical Implications
At a Glance
Category
Detail
Condition
Cardiac ischemia–reperfusion injury (IRI)
Key Mechanisms
Mitochondrial dysfunction due to Ca2+ overload, oxidative stress, mPTP opening, and lipid membrane alterations
Target Population
Patients with myocardial infarction (especially STEMI), stroke, and those undergoing major surgeries involving ischemia-reperfusion
Care Setting
Acute cardiac care settings including PCI and CABG interventions
Key Highlights
IRI exacerbates myocardial injury through oxidative stress and mitochondrial permeability transition pore (mPTP) opening.
Melatonin protects mitochondria by scavenging ROS, preserving electron transport chain function, and maintaining mitochondrial integrity.
Despite promising preclinical cardioprotective effects of melatonin, clinical trials have shown neutral outcomes, highlighting translational challenges.
Guideline-Based Recommendations
Diagnosis
Recognize IRI as a complication following reperfusion therapies such as PCI and CABG in acute MI patients.
Monitor for signs of myocardial injury exacerbation post-revascularization.
Management
Timely reperfusion remains mandatory to restore oxygen and nutrients to ischemic myocardium.
Consider experimental approaches targeting mitochondrial function, including antioxidant therapies like melatonin, though clinical efficacy remains unproven.
Use reperfusion strategies (PCI preferred in STEMI; CABG for complex anatomy or PCI failure) with awareness of IRI risk.
Monitoring & Follow-up
Assess cardiac function and infarct size post-reperfusion to evaluate extent of IRI.
Monitor for complications such as heart failure and arrhythmias linked to IRI.
Risks
IRI contributes to up to 50% of final infarct size after reperfusion.
Ca2+ overload and oxidative stress trigger irreversible mitochondrial injury and cardiomyocyte death.
Clinical interventions may paradoxically worsen myocardial injury through IRI.
Patient & Prescribing Data
Patients undergoing reperfusion therapy for acute myocardial infarction, especially STEMI patients
Melatonin shows significant cardioprotection in preclinical models by reducing infarct size and improving cardiac function, but clinical trials have not confirmed these benefits.
Clinical Best Practices
Prioritize rapid reperfusion to limit ischemic damage despite risk of IRI.
Recognize the central role of mitochondrial dysfunction in IRI pathophysiology.
Consider ongoing research into mitochondria-targeted therapies, including melatonin, while awaiting robust clinical evidence.
Monitor patients closely post-revascularization for signs of IRI-related complications.
